MarketPulse

Phase 1/2 trial

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Revolution Medicines

Revolution Medicines' Daraxonrasib Achieves NEJM Publication on Pancreatic Cancer Progress

Revolution Medicines published Phase 1/2 daraxonrasib data in NEJM, demonstrating promising activity in RAS mutant pancreatic cancer and supporting Phase 3 trial initiation.
RVMDRVMDWclinical trial resultspancreatic cancer
BenzingaBenzinga··Vandana Singh

Takeda Exits Dementia Drug Partnership With Denali in Strategic Shift

Takeda exits dementia drug partnership with Denali Therapeutics on DNL593. Denali regains full control, plans Phase 1/2 data release by end-2026. Denali shares fell 3.73%.
TAKDNLIPhase 1/2 trialbiotech collaboration
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Actuate Therapeutics to Unveil Cancer Pipeline Expansion at Citizens Conference

Actuate Therapeutics plans to present at the Citizens Life Sciences Conference on March 10, advancing elraglusib tablet into Phase 1/2 oncology trials launching H2 2026.
ACTUcancer therapypipeline expansion